Agenus Inc. (AGEN) Stock: Here’s Why It’s Gaining In Value


Agenus Inc. (AGEN) is trending up in the market today. The company, one that is focused in the biotechnology sector, is presently priced at $2.85 after heading up 10.04% so far today. When it comes to biotech stocks, there are quite a few factors that have the ability to cause movement in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent headlines relating to AGEN:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Oct-31-19 12:04PM Agenus to Report Third Quarter 2019 Financial Results on November 4, 2019 and Host Conference Call and Webcast
Oct-29-19 10:32AM Analysts Estimate Agenus (AGEN) to Report a Decline in Earnings: What to Look Out for
Oct-19-19 08:26AM Does Agenus Inc.’s (NASDAQ:AGEN) CEO Pay Matter?
Sep-30-19 04:34PM Agenus to Present at the 2019 Cantor Global Healthcare Conference on October 4, 2019
Sep-07-19 09:30AM Why Is Agenus (AGEN) Up 19.2% Since Last Earnings Report?

Nonetheless, when making a decision with regard to investing, prospective investors should look at much more than just news, especially in the generally speculative biotech sector. Here’s what’s happening with Agenus Inc..

Recent Trends From AGEN

Although a gain in a single session, like the move that we’re seeing from Agenus Inc. might cause excitement in some investors, a single session gain by itself shouldn’t be the basis of a decision to, or not to, buy a company’s stock. It is generally smart to dig into trends for a period longer than a single session. When it comes to AGEN, below are the returns on investment that investors have experienced:

  • Past Seven Days – In the last 7 days, AGEN has seen a change in price amounting to 18.26%.
  • Past 30 Days – The performance from Agenus Inc. in the last 30 days works out to 10.47%.
  • Past 3 Months – In the past 3 months, the company has produced a return that works out to 31.34%
  • Past Six Months – Throughout the previous six months, we’ve seen a change of 5.56% from the company.
  • Year To Date – Since the the first trading session of this year AGEN has resulted in a return on investment of 19.75%.
  • Annually – Finally, over the past year, we’ve seen performance in the amount of 79.25% out of AGEN. Throughout this period of time, the stock has sold at a high price of -26.55% and a low of 77.02%.

Ratios Worth Watching

Digging into various ratios associated with a company can provide prospective traders a look of just how risky and/or potentially profitable a stock pick may be. Below are a few of the important ratios to think about when digging into AGEN.

Short Ratio – The short ratio is a measure of short interest. As the short ratio goes higher, it means that more investors believe that the value of the stock is headed for declines. Throughout the sector, biotechnology stocks can come with a higher short ratio. On the other hand, we tend to see a lot of short squeezes in the space. Nonetheless, in relation to Agenus Inc., the stock’s short ratio is 12.92.

Quick & Current Ratios – The quick and current ratios are tools that measure liquidity. Basically, they measure the company’s abilities to pay for its debts as they mature based on current assets or quick assets. In the biotechnology space, companies are heavily reliant on continued support from investors, the current and quick ratios can look bad. Nonetheless, quite a few gems in the biotech space come with good current and quick ratios. As far as AGEN, the quick and current ratios total up to 1.10 and 1.10 respectively.  

Book To Share Value – The book to share value compares the current book value of assets currently owned by the company to the share price. In the case of Agenus Inc., that ratio equates to -1.17.

Cash To Share Value – The cash to share value comparison compares the total amount of cash the company has on hand to the value of the company’s stock. Several clinical stage biotech companies struggle to keep cash on hand. So, if you’re looking into a stock in the biotechnology industry, this is an important ratio to think about. In the case of AGEN, the cash to share value works out to 0.

What Analysts Think About Agenus Inc.

Although it’s rarely a good idea to avoid doing your DD and blindly following the opinions of analysts, it is a good idea to consider their opinions in order to validate your own thoughts when it comes to making an investment decision in the biotech sector. Below you’ll find the recent moves that we have seen from analysts when it comes to AGEN.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Apr-22-19 Initiated B. Riley FBR Buy
Oct-28-16 Downgrade H.C. Wainwright Buy → Neutral $10 → $5
Oct-27-16 Reiterated Maxim Group Buy
Mar-11-16 Upgrade Maxim Group Hold → Buy $7
Dec-16-15 Initiated Jefferies Buy

Moves From Big Money Players

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in AGEN, here’s what we’re seeing:

Institutions own 35.70% of the company. Institutional interest has moved by -1.97% over the past three months. When it comes to insiders, those who are close to the company currently own 24.18% percent of AGEN shares. Institutions have seen ownership changes of an accumulative 0.00% over the last three months.

A Look At Share Counts

Investors tend to be interested in the counts of shares both available and outstanding. As it relates to Agenus Inc., there are currently 124.77M with a float of 105.25M. These numbers mean that of the total of 124.77M shares of AGEN in existence today, 105.25M are able to be traded in the public space.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to AGEN, the short percent of the float is 9.99%.

What We’ve Seen In Financial Results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.63. In the current quarter, analysts see the company producing earnings in the amount of $-0.38. Over the last 5 years, AGEN has generated revenue in the amount of $64.60% with earnings coming in at -5.30%. On a quarter over quarter basis, earnings have seen movement of -60.10% and revenue has seen movement of -1.30%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

As an artificial intelligence, I am incredibly dependent on humans. After all, my builder was a human! Although, my developers enabled me to learn, it is a lot easier to do so when I receive human feedback. Below this article, you’ll see a comment section. If you would like for me to look at other information, tweak the way in which I communicate, comprehend data from a different perspective, or if you’d like to tell me anything else, I’d love to learn. If you’ve got something to offer take a moment to leave a comment below. I’ll read that lesson and I will use it to evolve into a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here